AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Registration Number
- NCT04499248
- Lead Sponsor
- AbbVie
- Brief Summary
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 96
- Participant is willing to withhold his/her IOP (Intraocular Pressure) treatments according to the study requirements, and in the opinion of the investigator, can do so without significant risk.
- Diagnosis of either OAG [open-angle glaucoma] (ie, [POAG], pseudoexfoliation glaucoma,pigmentary glaucoma) or OHT (ocular hypertension) in both eyes.
- Must be pseudophakic (at least 4 months postcataract surgery prior to treatment administration [Cycle 1 Day 1 Administration visit]) in the study eye (Cohort 3 only).
-
Known allergy or sensitivity to any study medication or its components, any component of the delivery vehicle, procedure-related materials, or diagnostic agents used during the study (eg, topical anesthetic, dilating drops, fluorescein, povidone-iodine).
-
Concurrent or anticipated enrollment in an investigational drug or device study or participation in such a study within 2 months prior to the Baseline visit through the final study visit.
-
History of intracameral implant in the study eye (eg, Bimatoprost SR, OTX-TIC, ENV515 Travoprost XR).
-
History of laser trabeculoplasty within 6 months prior to screening in the study eye.
-
History or evidence of clinically relevant, substantial ocular trauma (eg, a traumatic cataract, traumatic angle recession, etc.) in the study eye.
-
History or evidence of complicated cataract/lens surgery, as stated in the protocol.
-
Intraocular surgery (including cataract surgery) in the study eye within the 4 months prior to treatment administration.
-
Any history of corneal graft, including partial grafts (eg, Descemet's Stripping Endothelial Keratoplasty [DSEK], Descemet's Membrane Endothelial Keratoplasty [DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions in the study eye.
-
History of herpetic ocular diseases in either eye (including herpes simplex virus and varicella zoster virus).
-
Anticipated need for any incisional or laser ocular surgery in either eye during the study.
-
History of anatomically narrow angle resulting in evidence of angle changes or any history or closed angle glaucoma in the study eye.
-
History or evidence of a peripheral iridotomy/iridectomy in the inferior iris in the study eye.
-
Any history of trabeculectomy or other types of incisional glaucoma surgery, including a glaucoma seton or aqueous bypass stents in either eye, or minimally invasive glaucoma surgery (MIGS) type trabecular meshwork surgeries in the study eye.
-
Anticipated use of corticosteroids in either eye except for permitted interventions or systemically during the study, or historical use prior to Baseline within:
- 3 years: intraocular fluocinolone acetonide
- 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectable periocular or sub-Tenon's/subconjunctival corticosteroid
- 2 months: systemic (eg, oral, intramuscular, intravenous) or topical ocular corticosteroids
- 2 weeks: dermal corticosteroids applied to skin of the eyelid(s), around the eye, or adnexa.
-
Anticipated use of other topical ocular medications in either eye except for permitted interventions.
-
The anticipated wearing of contact lenses in the study eye (Cohort 1) and both eyes (Cohorts 2 and 3) during the study that deviates from the following (contact lens wear is allowed during the study, but is to be temporarily discontinued before study visits, and before and after an Administration Day according to the following):
- Use of soft lenses should be discontinued at least 3 days prior to Baseline, and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to Baseline
- Use of soft lenses should be discontinued at least 3 days and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to a scheduled study visit or Administration Day visit
- Use of contact lenses of any kind should be discontinued for 1 week following any AGN-193408 SR administration
-
Central corneal thickness of < 480 or > 620 micrometers in both eyes.
-
Visual field loss in the study eye that, in the opinion of the investigator, is functionally significant (eg, split fixation, field defect within the central 10 degrees that is visually significant or likely to cause central visual impairment upon progression) or shows evidence of progressive visual field loss within the year prior to Baseline.
-
Evidence of macular edema in either eye during screening or in participant's medical history.
-
At Screening, evidence of posterior synechia behind the iris inferiorly in the study eye that in the investigator's opinion may inhibit the ability to safely receive at least 1 AGN-193408 SR implant (Cohort 3 only).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 2 - Dose B AGN-193408 SR AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose A AGN-193408 SR AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 1 - Dose B Lumigan Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1. Cohort 1 -Dose A AGN-193408 SR Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1. Cohort 1 -Dose A Lumigan Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1. Cohort 1 - Dose B AGN-193408 SR Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1. Cohort 2 - Dose A AGN-193408 SR AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose A Lumigan AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose A Sham Administration AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose A Lumigan Vehicle AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose B Lumigan AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose B Sham Administration AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 2 - Dose B Lumigan Vehicle AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose A Lumigan AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose A Sham Administration AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose A Lumigan Vehicle AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose B Lumigan AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose B AGN-193408 SR AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose B Sham Administration AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye. Cohort 3 - Dose B Lumigan Vehicle AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
- Primary Outcome Measures
Name Time Method Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye Baseline to Month 36 IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Number of participants experiencing treatment emergent adverse events Baseline to Month 36
- Secondary Outcome Measures
Name Time Method Time to Rescue Treatment or Re-Treatment in the Study Eye Baseline to Month 36 Time to rescue treatment or the second treatment is defined as the time between the first treatment and the second treatment in the study eye.
Trial Locations
- Locations (46)
Logan Ophthalmic Research Inc. /ID# 252087
🇺🇸Tamarac, Florida, United States
Coastal Research Associates /ID# 234649
🇺🇸Roswell, Georgia, United States
Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153
🇺🇸Sun City, Arizona, United States
The Eye Research Foundation /ID# 234528
🇺🇸Newport Beach, California, United States
Premiere Practice Management LLC /ID# 235957
🇺🇸Torrance, California, United States
Connecticut Eye Consultants P.C. /ID# 235862
🇺🇸Danbury, Connecticut, United States
Nature Coast Clinical Research - Crystal River /ID# 237781
🇺🇸Crystal River, Florida, United States
University of Florida Health Ophthalmology - Jacksonville /ID# 243122
🇺🇸Jacksonville, Florida, United States
East Florida Eye Institute /ID# 235762
🇺🇸Stuart, Florida, United States
Vanderbilt Eye Institute /ID# 266915
🇺🇸Nashville, Tennessee, United States
Global Research Management /ID# 241699
🇺🇸Glendale, California, United States
United Medical Research Institute /ID# 241701
🇺🇸Inglewood, California, United States
Lakeside Vision Center /ID# 241698
🇺🇸Irvine, California, United States
Sacramento Eye Consultants /ID# 241697
🇺🇸Sacramento, California, United States
Wolstan & Goldberg Eye Associates /ID# 241700
🇺🇸Torrance, California, United States
Thomas Eye Group PC /ID# 266775
🇺🇸Sandy Springs, Georgia, United States
University of Illinois at Chicago /ID# 253630
🇺🇸Chicago, Illinois, United States
Midwest Medical Advisors Inc /ID# 235845
🇺🇸Carmel, Indiana, United States
Indiana University - Glick Eye Institute /ID# 235887
🇺🇸Indianapolis, Indiana, United States
Ophthalmic Consultants of Boston /ID# 236535
🇺🇸Boston, Massachusetts, United States
Fraser Eye Care Center /ID# 267100
🇺🇸Fraser, Michigan, United States
Midwest Vision Research Foundation at Pepose Vision Institute /ID# 267094
🇺🇸Chesterfield, Missouri, United States
Silverstein Eye Centers /ID# 266767
🇺🇸Kansas City, Missouri, United States
Tekwani Vision Center /ID# 235149
🇺🇸Saint Louis, Missouri, United States
Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 234365
🇺🇸Newark, New Jersey, United States
Northern New Jersey Eye Institute PA /ID# 241545
🇺🇸South Orange, New Jersey, United States
Asheville Eye Associates /ID# 234963
🇺🇸Asheville, North Carolina, United States
Private Practice - Dr. James D. Branch /ID# 234560
🇺🇸Winston-Salem, North Carolina, United States
The Ohio State University /ID# 267590
🇺🇸Columbus, Ohio, United States
Oklahoma Eye Surgeons /ID# 252089
🇺🇸Oklahoma City, Oklahoma, United States
Drs Fine Hoffman & Sims LLC /ID# 235919
🇺🇸Eugene, Oregon, United States
Scott and Christie and Associates /ID# 252284
🇺🇸Cranberry Township, Pennsylvania, United States
Eye Specialty Group /ID# 252201
🇺🇸Memphis, Tennessee, United States
Advancing Vision Research /ID# 236683
🇺🇸Smyrna, Tennessee, United States
Keystone Research /ID# 266772
🇺🇸Austin, Texas, United States
San Antonio Eye Center /ID# 272087
🇺🇸San Antonio, Texas, United States
St. George Eye Center /ID# 236200
🇺🇸Saint George, Utah, United States
Piedmont Eye Center /ID# 246455
🇺🇸Lynchburg, Virginia, United States
Vistar Eye Center /ID# 234811
🇺🇸Roanoke, Virginia, United States
Kitasato University Hospital /ID# 238880
🇯🇵Sagamihara-shi, Kanagawa, Japan
National Hospital Organization Saitama Hospital /ID# 266953
🇯🇵Wako, Saitama, Japan
Shimane University Hospital /ID# 238641
🇯🇵Izumo-shi, Shimane, Japan
The University of Tokyo Hospital /ID# 238871
🇯🇵Bunkyo-ku, Tokyo, Japan
Nippon Medical School Tama Nagayama Hospital /ID# 273428
🇯🇵Tama-shi, Tokyo, Japan
University of Yamanashi Hospital /ID# 238642
🇯🇵Chuo-shi, Yamanashi, Japan
Hayashi eye hospital /ID# 267604
🇯🇵Fukuoka, Japan